Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma
Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group. The deal, which is expected to close in 2025’s third quarter, will set up Tanabe Pharma as an independent company, Bain said.
Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group. The deal, which is expected to close in 2025’s third quarter, will set up Tanabe Pharma as an independent company, Bain said.
